Edition:
United States

Takeda Pharmaceutical Co Ltd (TKPYY.PK)

TKPYY.PK on OTC Markets Group

26.03USD
--
Change (% chg)

-- (--)
Prev Close
$26.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
44,790
52-wk High
$26.17
52-wk Low
$19.96

TKPYY.PK

Chart for TKPYY.PK

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)
No analyst recommendations are available for TKPYY.PK.

Overall

No Ratios Available.

Financials

  TKPYY.PK Industry Sector
P/E (TTM): -- 14.35 17.42
EPS (TTM): -- -- --
ROI: -- -7.29 -5.45
ROE: -- -6.80 -4.73

BRIEF-Teva Takeda Pharma to up overseas production of generic medication to cut costs - Nikkei

* Teva takeda pharma to increase overseas production of generic medication to cut costs per year as drug prices continue to decline - Nikkei Source text (http://s.nikkei.com/2qOMEN4) Further company coverage:

May 16 2017

BRIEF-Takeda Pharmaceutical announces further details of transformational pharmaceutical sciences partnership with Bushu

* Says it has entered into an agreement for an absorption-type company split with its wholly-owned subsidiary, SPERA PHARMA, Inc. on May 15

May 15 2017

BRIEF-Takeda Pharmaceutical to transfer partial pharmaceutical research businesses to succeeding company

* Says it will transfer a part of Takeda's pharmaceutical research businesses to the succeeding company, effective July 1

May 15 2017

BRIEF-Biologics Inc says selected by Takeda to be specialty pharmacy provider

* Selected by Takeda Pharmaceutical through unit to be specialty pharmacy provider as part of distribution network for Alunbrig (Brigatinib) Source text for Eikon: Further company coverage:

May 11 2017

U.S. FDA approves Takeda's lung cancer drug as second-line treatment

Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc.

Apr 28 2017

U.S. FDA approves Takeda's lung cancer drug as 2nd-line treatment

April 28 Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc.

Apr 28 2017

BRIEF-Takeda announces FDA accelerated approval of ALUNBRIG

* Takeda announces FDA accelerated approval of ALUNBRIG(brigatinib)

Apr 28 2017

BRIEF-Takeda, Harrington Discovery Institute announce collaboration

* Takeda and Harrington Discovery Institute at University Hospitals announce a collaboration to advance the development of Rare Disease Therapeutics Source text for Eikon: Further company coverage:

Apr 27 2017

Deals of the day-Mergers and acquisitions

April 25 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Tuesday:

Apr 25 2017

BRIEF-Aquinnah receives $10 mln investment from Pfizer, Abbvie

* Aquinnah Pharmaceuticals receives $10 million investment from Pfizer and Abbvie to research breakthrough approach to neurodegenerative disease

Apr 25 2017

More From Around the Web

Earnings vs. Estimates

No consensus analysis data available.